Methods and materials for treating cancer
This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.
1. A method for reducing the number of renal cell carcinoma cells within a mammal, wherein said method comprises administering, to said mammal, an inhibitor of an SCD1 polypeptide and an inhibitor of an mTor polypeptide under conditions wherein the number of viable renal cell carcinoma cells present within said mammal is reduced.
2. The method of claim 1 , wherein said inhibitor of an mTor polypeptide is sirolimus (RAPAMUNE®), temsirolimus (CCI-779), everolimus (RAD001), or ridaforolimus (AP-23573).
3. The method of claim 1 , wherein said mammal is a human.
4. The method of claim 1 , wherein said administration is an intratumoral, oral, intraperitoneal, intramuscular, or intravenous administration.
5. The method of claim 1 , wherein said inhibitor of an SCD1 polypeptide is A939572, MK-8245, CVT-11127, MF-152, or HYR-061.
6. A method for reducing the number of renal cell carcinoma cells within a mammal, wherein said method comprises administering, to said mammal, an inhibitor of an SCD1 polypeptide under conditions wherein the number of viable renal cell carcinoma cells present within said mammal is reduced.
7. The method of claim 6 , wherein said mammal is a human.
8. The method of claim 6 , wherein said administration is an intratumoral, oral, intraperitoneal, intramuscular, or intravenous administration.
9. The method of claim 6 , wherein said inhibitor is A939572, MK-8245, CVT-11127, MF-152, or HYR-061.
10. The method of claim 6 , wherein said mammal is further administered an inhibitor of a mTor polypeptide.
11. The method of claim 10 , wherein said inhibitor is sirolimus (RAPAMUNE®), temsirolimus (CCI-779), everolimus (RAD001), or ridaforolimus (AP-23573).
12. A method for reducing the number of renal cell carcinoma cells within a mammal, wherein said method comprises administering, to said mammal, a composition under conditions wherein the number of viable renal cell carcinoma cells present within said mammal is reduced, wherein said composition comprises the ability to reduce SCD1 mRNA expression or SCD1 polypeptide expression.
13. The method of claim 12 , wherein said mammal is a human.
14. The method of claim 12 , wherein said administration is an intratumoral, oral, intraperitoneal, intramuscular, or intravenous administration.
15. The method of claim 12 , wherein said composition comprises a nucleic acid construct having the ability to express an shRNA directed against SCD1 nucleic acid.